Hangzhou Bio Sincerity Pharmaceutical describes new histamine H3 receptor antagonists
Oct. 2, 2023
Hangzhou Bio Sincerity Pharmaceutical Technology Co. Ltd. has identified histamine H3 receptor antagonists reported to be useful for the treatment of pain, attention deficit hyperactivity disorder, schizophrenia, epilepsy, sleep disorders, obesity, eating disorder, neuropathic pain and itching.